• Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

Sign up for our Moneywise newsletter to receive a steady flow of actionable ideas from Wall Street's top firms.

Bank of America (BAC)

Bank of America is a $295 billion financial holding company, with a leading U.S. and global footprint.

Generally speaking, the banking business is positively impacted by rising interest rates. When rates increase, the spread between what banks charge in interest and what they pay out widens.

Bank of America has a high proportion of its assets in low-cost consumer deposits relative to peers. In other words, rising interest rates should benefit Bank of America to a greater degree than many of its competitors. Conservative underwriting and a measured risk-taking appetite should also help the bank take advantage of its scale and opportunities in a responsible way.

The bank is enjoying resilient consumer and strong lending markets. Over the past few quarters, earnings have come in better than expected.

Bank of America shares are down 20% so far in 2022. Rapidly rising rates could serve as a powerful turnaround catalyst.

Invest in real estate without the headache of being a landlord

Imagine owning a portfolio of thousands of well-managed single family rentals or a collection of cutting-edge industrial warehouses. You can now gain access to a $1B portfolio of income-producing real estate assets designed to deliver long-term growth from the comforts of your couch.

The best part? You don’t have to be a millionaire and can start investing in minutes.

Learn More

Merck (MRK)

Healthcare companies can also serve as a safe haven in a rising rate environment. Their resilient nature makes them relatively immune to the economic turbulence that higher rates can bring.

On top of that, the healthcare sector hasn’t exactly soared in recent years, so valuations are compelling.

Healthcare giant Merck — a $214 billion global healthcare company — represents a solid way to gain access to the sector. It has leading oncology and cardiovascular disease franchises.

2021 was a strong year for Merck. It posted revenue and EPS growth of 17% and 7.3%, respectively, due to strong operational momentum. Currently, the stock offers a dividend yield of 3.2%.

Cheniere Energy (LNG)

Cheniere Energy is the leading producer and exporter of liquefied natural gas in the U.S. Thanks to white-hot inflation, the company is benefiting from soaring natural gas prices. Since interest rates are tied to rising energy prices, Chenier looks like a particularly timely opportunity.

Cheniere is also enjoying a very favorable global supply/demand dynamic, which shows no signs of letting up. Last month, U.S. LNG exports rose 16% to a record high as European countries tried to cut down on Russian gas imports.

Record global LNG demand has resulted in record revenue, volumes and cash flow for Cheniere. The shares are up an impressive 36% in 2022.

Sign up for our Moneywise newsletter to receive a steady flow of actionable ideas from Wall Street's top firms.

Retire richer: The secret to building wealth faster

Most people miss out on key opportunities to grow their wealth. Partnering with the right financial advisor can help you secure a brighter future. Learn how to make your money work harder for you today.

Discover the secret

More from Moneywise

The richest 1% use an advisor. Do you?

Wealthy people know that having money is not the same as being good with money. Advisor.com can help you shape your financial future and connect with expert guidance . A trusted advisor helps you make smart choices about investments, retirement savings, and tax planning.

Try it now
Karen Thomas, CFA Freelance Contributor

Karen Thomas, CFA, is a freelance contributor to Moneywise.

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter. Advertisers are not responsible for the content of this site, including any editorials or reviews that may appear on this site. For complete and current information on any advertiser product, please visit their website.

†Terms and Conditions apply.